PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

Gary R Lichtenstein Selected Research

infliximab (Remicade)

12/2006	Infliximab in fistulizing Crohn's disease.
12/2006	Infliximab in ulcerative colitis.
07/2006	[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]
03/2006	American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
03/2006	Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject--that is the question.
03/2006	Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
03/2006	American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
12/2005	Infliximab for induction and maintenance therapy for ulcerative colitis.
07/2005	Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
04/2005	Infliximab use in Crohn's disease.
04/2005	Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.
12/2004	Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
08/2004	Incorrect cost of infliximab in fistulizing Crohn's disease.
02/2004	Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
11/2003	Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
08/2003	Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
06/2003	Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?
07/2002	Infliximab improves quality of life in patients with Crohn's disease.
05/2002	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Articles by Research Topic

Disease

16	Crohn Disease (Crohn's Disease) 12/2006 - 04/2002
11	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2008 - 08/2003
9	Ulcerative Colitis 03/2008 - 10/2002
1	Colorectal Neoplasms (Colorectal Cancer) 02/2008
1	Adenoma (Adenomas) 01/2008
1	Ulcer 03/2006
1	Rheumatoid Arthritis 12/2004
1	Pyoderma Gangrenosum 08/2003
1	Ischemic Colitis 08/2002

Drug/Important Bio-Agent (IBA)

19	infliximab (Remicade)FDA Link 12/2006 - 05/2002
5	Adrenal Cortex Hormones (Corticosteroids)IBA 07/2006 - 04/2002
4	Immunologic Factors (Immunomodulators)IBA 07/2006 - 08/2003
3	Mesalamine (Mesalazine)FDA LinkGeneric 02/2008 - 01/2007
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2006 - 10/2002
1	rosiglitazone (Avandia)FDA Link 03/2008
1	6-thioguanylic acidIBA 04/2006
1	AntioxidantsIBA 04/2005
1	6-Mercaptopurine (Mercaptopurine)FDA LinkGeneric 06/2004
1	Azathioprine (Imuran)FDA LinkGeneric 06/2004
1	Glycoproteins (Glycoprotein)IBA 08/2002
1	Sodium Glutamate (Accent)IBA 05/2002

Therapy/Procedure

2	Colectomy 01/2008 - 06/2005
1	Remission Induction 01/2007
1	Chemoprevention 09/2006
1	Biological Therapy 01/2006
1	Enema (Enemas) 06/2005